VPM is running one of the projects supported by covidX – an initiative which maps different approaches to overcome COVID-19.
The global COVID-19 pandemic has grave health, societal, and economic consequences. The exact impact is uncertain and raises many questions. At the same time, both the lack of validated data and the mass of unfiltered information gives false hope and raises insecurity.
CovidX aims to provide the public with up-to-date and accurate information on potential diagnostics, vaccines and therapeutics against COVID-19. To map those initiatives in the area of COVID-19 covidX supports to ensure transparency in this space.
VPM is coordinator of the priMe project, that evaluates the efficacy and safety of a new vaccine candidate against tuberculosis (TB).
TB is one of the top 10 causes of death worldwide. An estimated 10 million people fell ill with TB in 2017 with approximately 1.3 million dying from the disease. In children, BCG vaccination can protect against, or at least ameliorate, severe forms of systemic TB, particularly TB meningitis. Ultimately, to interrupt transmission of the disease, highly contagious pulmonary forms of TB also need to be targeted by vaccination.
VPM is partner in the consortium and will act as sponsor of the Cruzivax project that targets the development of a vaccine for prevention and treatment of T. cruzi infection.
Chagas is a neglected disease endemic in 21 Latin-American countries caused by Trypanosoma cruzi. It is the largest parasitic disease burden in the Americas (> 11.000.000 chronic infections) and the first cause of cardiac morbidity in poor rural/suburban areas. It became a worldwide concern as a result of mass migration with reports in 19 non-endemic areas (> 1.3 million carriers in EU/USA).
The development of the vaccine will strengthen the pipeline of products for Chagas disease, aimed at reducing disease burden and its social and economic impact.